WALVAX BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.33 CNY | +3.54% |
|
+2.43% | -39.05% |
| Apr. 26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
| Apr. 25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
ETFs positioned on Walvax Biotechnology Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.09% | 2 M€ | -16.59% | - | |
| 0.54% | 2 M€ | -14.14% | ||
| 0.23% | 35 M€ | -5.85% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 441 M€ | +4.60% | - | |
| 0.00% | 2,808 M€ | +5.90% | - | |
| 0.00% | 149 M€ | +2.17% | - | |
| 0.00% | 31 M€ | +3.50% | - | |
| 0.00% | 389 M€ | +6.83% | - | |
| 0.00% | 34 M€ | +4.85% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 108 M€ | +2.03% | - | |
| 0.00% | 17 M€ | +0.50% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 52 M€ | -0.60% | - |
Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
14.33
CNY
Average target price
20
CNY
Spread / Average Target
+39.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.05% | 3.16B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 300142 Stock
- Funds and ETFs Walvax Biotechnology Co., Ltd.
